Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single Ascending Dose Study for the Evaluation of the Effects of LY3039478 on the QT/Corrected QT Interval in Healthy Subjects and Pilot Relative Bioavailability

Trial Profile

A Single Ascending Dose Study for the Evaluation of the Effects of LY3039478 on the QT/Corrected QT Interval in Healthy Subjects and Pilot Relative Bioavailability

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Crenigacestat (Primary)
  • Indications Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 30 Oct 2017 Results from this and 2 otehr studies, presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017
    • 25 Oct 2017 Outcomes of population PK/PD model developed using data from first human dose trial (NCT01695005,n=102) and single ascending dose and pilot relative bioavailability study (NCT02659865,n=34),presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2017.
    • 11 Jul 2016 Status changed from recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top